AbbVie Inc.

Good morning and thank you for standing by. Welcome to AVI Second Quarter 2025 Earnings Conference Call. Our participants will be able to listen only until the question and answer portion of this call. You may ask a question by pressing star one on your phone. Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior Vice President of Investor Relations. Ma'am, you may begin.

Thank you, good morning and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer, Jeff Stewart, Executive Vice President, Chief Commercial Officer, Rupal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, and Scott Runtz, Executive Vice President, Chief Financial Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. Advocations that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. ABVI undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand ABVI's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.

Thank you, Liz. Good morning, everyone, and thank you for joining us. ABVI delivered another outstanding quarter, with results exceeding our expectations. We are making excellent progress advancing our pipeline and adding more depth through strategic transactions that support our long-term growth. Turning to our second quarter performance, we delivered adjusted earnings per share of $2.97, which is 11 cents above our guidance midpoint. Total net revenues were $15.4 billion, more than $400 million ahead of our expectations. This overachievement includes sales growth of 22% from our ex-Humira platform, with continued robust performance from Sky Rizzi and Rindvog, which are now on pace to deliver more than $25 billion in combined sales this year, well above our initial expectations. We also delivered strong double-digit growth from neuroscience, driven by Vrelar, Vilev, and our leading migraine portfolio. Based on our momentum through the first half of the year, we are raising guidance for the second time. We now expect full year revenue of $60.5 billion, an increase of $800 million. We have now raised our revenue guidance by $1.5 billion since the start of the year. We are also raising our full year adjusted earnings per share guidance by 21 cents, and now expect adjusted EPS between $11.88 and $12.08. In addition to our strong financial results, we are making great progress with our R&D pipeline across all stages of development. Notable highlights from our late stage programs include the recent approvals of Emerilis for non-squamous non-small cell lung cancer, and Rindvog for GCA, the regulatory submission of Trennabot E, a first in class short acting toxin in aesthetics, as well as highly differentiated phase three results in alopecia areata, a potential 10th indication for Rindvog in the US. We are also focused on augmenting our pipeline with therapies and platform technologies that have the potential to elevate the standard of care for patients. These include promising early stage programs that have the potential to drive growth for ABBEE in the next decade. We have executed more than 30 business development transactions since the beginning of last year. Our recent activity includes closing the agreement with GUBRA for a long acting amylin analog in the treatment of obesity, as well as announcing our planned acquisition of capstan therapeutics, giving us an in vivo CAR T platform that can further strengthen our immunology pipeline. We also in licensed ISB 2001, a novel tri specific antibody for multiple myeloma. And we announced the collaboration with ADARx to develop next generation siRNA therapies across multiple disease areas, including immunology, neuroscience and oncology. In summary, I'm very pleased with the performance of our business and the progress we are making against our longterm strategy. ABBEE's outlook is strong and we are well positioned to deliver on our commitments in 2025 and beyond. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights. Jeff.